Le Lézard
Classified in: Health, Science and technology
Subjects: BLK, MIN, DEI

Mount Sinai Health System Launches Mobile Prostate Cancer Screening Unit in New York City


An initiative to support prostate health in the Black community. B-roll video surrounding the Robert F. Smith Mobile Prostate Cancer Unit is available upon request.

NEW YORK, April 4, 2022 /PRNewswire-PRWeb/ -- The Milton and Carroll Petrie Department of Urology at Mount Sinai has launched the Mount Sinai Robert F. Smith Mobile Prostate Cancer Screening Unit to support prostate health in the Black community.

The mobile van is equipped to perform screenings and tests including the prostate-specific antigen test, digital rectal exam, ExactVutm micro-ultrasound system, EchoNous bladder scanner, genomics testing, and more.

The mobile unit was created to address the disproportionately high incidence of prostate cancer in the Black community?Black men are 70 percent more likely to develop high-risk prostate cancer, and are also more than twice as likely to die of the disease, as white men.

In the United States, prostate cancer is the second-most-common form of cancer in men, following skin cancer. About 1 in 40 American men will die of prostate cancer and Black men are more at risk. Early prostate cancer detection is the best way to keep healthy. The American Urological Association recommends that all men above age 55, and all Black men above age 45, consult with their doctor to discuss the benefits of screening.

"The Robert F. Smith Mobile Prostate Cancer Screening Unit will be an invaluable service for the community, allowing us to meet our patients where they are," says Ash Tewari, MBBS, MCh, Chair of Urology at the Mount Sinai Health System and the Kyung Hyun Kim, MD Professor of Urology at the Icahn School of Medicine at Mount Sinai. "Our goal is that with increased education, awareness, and access to testing, we can help detect prostate cancer early, save lives, and close the gaps in high-risk diagnostic and fatality rates."

"With Black men at an increased risk of both being diagnosed with and dying from prostate cancer, getting these life-saving resources for testing and treatment into our communities has never been more urgent," said Robert F. Smith, Founder, Chairman, and CEO of Vista Equity Partners. "I am proud to support Mount Sinai in these efforts to ensure we do not continue to lose far too many husbands, fathers, uncles, brothers, sons, and friends to this disease. This mobile screening unit will bring awareness and care right into the communities where they are most needed."

Mount Sinai Health System will join forces with local community partners to raise awareness about the disease and services offered by the mobile unit, set up prostate screening appointments at the mobile magnetic resonance imaging (MRI) unit in highly concentrated Black neighborhoods across New York City, and schedule follow-up visits as needed for patients with Mount Sinai Health System urologists.

The Mobile Unit will be making the following stops in the coming weeks:

Made possible by a donation from Mr. Smith, the mobile unit brings state-of-the-art imaging equipment and specialized staff directly to the communities that need them most. The initiative is led by Dr. Tewari, a world-renowned urologist and prostate cancer surgeon. As Director of the Center of Excellence for Prostate Cancer at Mount Sinai, he leads a multidisciplinary team committed to improving prostate cancer treatment, research, and education. The department is at the forefront of urological care and treats more than 100,000 patients annually.

The Department of Urology at the Mount Sinai Health System has one of the most robust robotic surgery programs in the country, with Dr. Tewari having performed more than 7,000 surgeries. Genomic testing and advanced imaging are routine for patients with prostate cancer, providing personalized and precise treatment protocols. Dr. Tewari and his team have performed thousands of MRI-guided fusion biopsies, have a very large cohort of active surveillance patients, and have been innovators in developing novel surgical techniques to optimize sexual function recovery and urinary continence.

Mount Sinai's Center of Excellence for Prostate Cancer at The Tisch Cancer Institute, under the leadership of Dr. Tewari, offers the most up-to-date diagnosis, management, and treatment approaches for prostate cancer. The team of world-renowned experts includes urologic, radiation, and medical oncologists, as well as impotence specialists, pathologists, radiologists, and oncology nurses.

More Information:

About the Mount Sinai Health System
The Mount Sinai Health System is New York City's largest academic medical system, encompassing eight hospitals, a leading medical school, and a vast network of ambulatory practices throughout the greater New York region. Mount Sinai advances medicine and health through unrivaled education and translational research and discovery to deliver care that is the safest, highest-quality, most accessible and equitable, and the best value of any health system in the nation. The Health System includes approximately 7,300 primary and specialty care physicians; 13 joint-venture ambulatory surgery centers; more than 415 ambulatory practices throughout the five boroughs of New York City, Westchester, Long Island, and Florida; and more than 30 affiliated community health centers. The Mount Sinai Hospital is ranked on U.S. News & World Report's "Honor Roll" of the top 20 U.S. hospitals and is top in the nation by specialty: No. 1 in Geriatrics and top 20 in Cardiology/Heart Surgery, Diabetes/Endocrinology, Gastroenterology/GI Surgery, Neurology/Neurosurgery, Orthopedics, Pulmonology/Lung Surgery, Rehabilitation, and Urology. New York Eye and Ear Infirmary of Mount Sinai is ranked No. 12 in Ophthalmology. Mount Sinai Kravis Children's Hospital is ranked in U.S. News & World Report's "Best Children's Hospitals" among the country's best in four out of 10 pediatric specialties. The Icahn School of Medicine is one of three medical schools that have earned distinction by multiple indicators: ranked in the top 20 by U.S. News & World Report's "Best Medical Schools," aligned with a U.S. News & World Report "Honor Roll" Hospital, and No. 14 in the nation for National Institutes of Health funding. Newsweek's "The World's Best Smart Hospitals" ranks The Mount Sinai Hospital as No. 1 in New York and in the top five globally, and Mount Sinai Morningside in the top 20 globally. For more information, visit https://www.mountsinai.org or find Mount Sinai on Facebook, Twitter and YouTube.

Media Contact

Lindsey Diaz-MacInnis, Mount Sinai Health System, 212-241-9200, [email protected]

 

SOURCE Mount Sinai Health System


These press releases may also interest you

18 mai 2024
Celltrion partners with TV star Mollie Pearce to launch the second installation of the Where's Crohn's & Colitis (CC)? campaign for this year's World IBD Day (19 May 2024). The campaign focuses on access to IBD care and treatment as the burden of...

18 mai 2024
On Wednesday, May 15, Red Door Community hosted their annual Celebrating Women Working and Living with Cancer Luncheon at the Metropolitan Club in New York City. The event raised more than $300,000 while shining a light on the women who inspire us...

18 mai 2024
Product: Kalihim (Philippine Bread Roll) Issue: Food - Allergen - Egg Distribution: British Columbia See the affected products and product photos for this recall SOURCE Canadian Food Inspection Agency (CFIA)

18 mai 2024
The global industrial automation market in life sciences industry  size is estimated to grow by USD 5.06 bn from 2024-2028, according to Technavio. The market is estimated to grow at a CAGR of  11.4%  during the forecast period. ...

18 mai 2024
Boston Scientific Corporation today announced positive six-month results from the ongoing pivotal MODULAR ATP clinical trial of the mCRMtm System,* the first modular cardiac rhythm management (CRM) system that consists of the EMBLEMtm Subcutaneous...

18 mai 2024
Gilead Sciences, Inc. , following the recent acquisition of CymaBay Therapeutics, Inc., today announced interim results from the ongoing ASSURE study demonstrating treatment with seladelpar, an investigational PPAR delta agonist, led to improvements...



News published on and distributed by: